Biomea Fusion Inc
NASDAQ:BMEA
Biomea Fusion Inc
Depreciation & Amortization
Biomea Fusion Inc
Depreciation & Amortization Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Depreciation & Amortization | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
Biomea Fusion Inc
NASDAQ:BMEA
|
Depreciation & Amortization
$1.7m
|
CAGR 3-Years
91%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
Abbvie Inc
NYSE:ABBV
|
Depreciation & Amortization
$8.3B
|
CAGR 3-Years
0%
|
CAGR 5-Years
11%
|
CAGR 10-Years
27%
|
|
|
Gilead Sciences Inc
NASDAQ:GILD
|
Depreciation & Amortization
N/A
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
Amgen Inc
NASDAQ:AMGN
|
Depreciation & Amortization
N/A
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
Astria Therapeutics Inc
NASDAQ:ATXS
|
Depreciation & Amortization
N/A
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
|
Depreciation & Amortization
$200.6m
|
CAGR 3-Years
11%
|
CAGR 5-Years
13%
|
CAGR 10-Years
12%
|
|
Biomea Fusion Inc
Glance View
Biomea Fusion, Inc. is a biopharmaceutical company, which engages in the discovery, development, and commercialization of irreversible small molecules to treat patients with genetically defined cancers. The company is headquartered in Redwood City, California and currently employs 51 full-time employees. The company went IPO on 2021-04-16. The firm is focused on the discovery, development and commercialization of irreversible small molecule drugs to treat patients with genetically defined cancers. The firm has built FUSION System discovery platform to advance a pipeline of irreversible small molecule product candidates. The firm's lead product candidate, BMF-219, is designed to be an orally bioavailable, potent and selective irreversible inhibitor of menin, an important transcriptional regulator known to play a direct role in oncogenic signaling in multiple cancers. The firm is developing BMF-219 for the treatment of liquid and solid tumors that are dependent on menin, including leukemias containing the mixed lineage leukemia (MLL) fusion protein. The firm is also advancing other preclinical irreversible programs for the treatment of select cancers.
See Also
What is Biomea Fusion Inc's Depreciation & Amortization?
Depreciation & Amortization
1.7m
USD
Based on the financial report for Dec 31, 2024, Biomea Fusion Inc's Depreciation & Amortization amounts to 1.7m USD.
What is Biomea Fusion Inc's Depreciation & Amortization growth rate?
Depreciation & Amortization CAGR 3Y
91%
Over the last year, the Depreciation & Amortization growth was 15%. The average annual Depreciation & Amortization growth rates for Biomea Fusion Inc have been 91% over the past three years .
